LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

LLY

1,084.9

+1%↑

JNJ

231.61

+0.29%↑

ABBV

214.93

+1.26%↑

UNH

381.61

+0.56%↑

AZN

186.94

-0.13%↓

Home・Lista de Ações・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abrir

SetorSaúde

31.28 -0.06

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.26

Máximo

31.34

Indicadores-chave
By Trading Economics
Rendimento	11M 64M
Vendas	-3.2M 149M
P/E Médio do Setor	18.052 49.701
EPS	0.79
Margem de lucro	42.663
Funcionários	182
EBITDA	2M 83M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+5.65% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	281M 3.8B
Abertura anterior	31.34
Fecho anterior	31.28

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Catalyst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mai. de 2026, 16:52 UTC

Notícias Principais

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q Rev $1.76B >SQM

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q EPS $1.28 >SQM

26 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q EPS $11.61 >WEBC

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q Sales $179.6M >WEBC

26 de mai. de 2026, 21:48 UTC

Conversa de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 de mai. de 2026, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

26 de mai. de 2026, 20:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 de mai. de 2026, 19:17 UTC

Conversa de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 de mai. de 2026, 18:56 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 de mai. de 2026, 18:03 UTC

Conversa de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 de mai. de 2026, 17:42 UTC

Conversa de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 de mai. de 2026, 17:33 UTC

Conversa de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 de mai. de 2026, 16:52 UTC

Conversa de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 de mai. de 2026, 16:43 UTC

Conversa de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 de mai. de 2026, 16:24 UTC

Conversa de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 de mai. de 2026, 16:21 UTC

Conversa de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 16:16 UTC

Conversa de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 de mai. de 2026, 16:01 UTC

Conversa de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 de mai. de 2026, 15:21 UTC

Conversa de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparação entre Pares

Variação de preço

Catalyst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

5.65% parte superior

Previsão para 12 meses

Média 33.1 USD 5.65%

Máximo 35 USD

Mínimo 31.5 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Catalyst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Catalyst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.